Kornimate/medical-research-clean huggingface dataset:
cushing's disease complications

Conditions: Cushing's Disease

Summary: this study aims at investigating the complications of cushing's disease in "de novo" patients. a series of investigations will assay before treatment and every year thereafter during a 3 years follow-up period the various complications of the disease. these investigations will determine the presence and severity of cardiovascular, metabolic, and bone complications as well as the quality of life. outcome of these complications after treatment, especially after pituitary surgery will be monitored, as well as cortisol levels.

at inclusion the following will be investigated and recorded : * demographic and personal medical history. * familial medical history related to osteoporosis, cardiovascular disorders and thromboembolism. * current medical treatment. * physical examination. * assessment of basal 24hrs urinary cortisol and salivary cortisol. - at baseline (i.e. before specific treatment of cortisol excess): * physical examination, * routine biology, * hba1c, fasting glucose and oral glucose load, * cholesterol, triglyceride, hdl \& ldl, * coagulation and fibrinolysis investigation, * 24hrs urinary cortisol and salivary cortisol, urinary labstick test. * ekg, cardiac ultrasound, cardiac ct-scan, arterial and venous us, * ophthalmology examination, * spine x-ray, bone densitometry, * qol questionnaires (sf-36, qolcushing, beck bdi-ii). every year during a 3 years follow-up the following will be investigated : * current medical treatment. * physical examination. * assessment of basal routine biology, * hba1c, fasting glucose, * cholesterol, triglyceride, hdl \& ldl, * coagulation and fibrinolysis investigation, * 24hrs urinary cortisol and salivary cortisol, urinary labstick test. * ekg, cardiac ultrasound, cardiac ct-scan (if abnormal initially), arterial and venous us, * ophthalmology examination, bone densitometry, * qol questionnaires (sf-36, qolcushing, beck bdi-ii).

Eligibility criteria:
inclusion criteria: * cushing's disease diagnosed by complementary explorations according to the national program of diagnosis and care of the cushing 's disease exclusion criteria: * other cause of cushing's syndrome * known inherited syndrome having for consequence an hormonal hypersecretion (nem-1, complexe of carney, mccunealbright syndrome) * patient does not understand french * life expectancy of less than 6 months * pregnant women * dependent patient

Keywords: cushing's disease quality of life metabolic patients with cushing's disease cardiovascular thromboembolic bone complications
clinical trial for zebinix (eslicarbazepine acetate) in healthy korean and caucasian adult

Conditions: Partial-onset Seizures With or Without Secondary Generalisation

Summary: a dose randomized, double-blind, placebo controlled, single and multiple dosing, dose-escalation phase i clinical trial to investigate the safety, tolerability and pharmacokinetic characteristics of zebinix (eslicarbazepine acetate) after oral administration in healthy korean and caucasian adult subjects


Eligibility criteria:
inclusion criteria: * healthy adult volunteers aged 19-45 years at screening * subjects who weigh more than 50kg with a body mass index(bmi) of 18.0\~28.0 kg/m2 at screening * subjects who are fully understood after being given the detailed explanation of this clinical trial and willing to give written informed consent for participation prior to the screening test * subjects who are qualified to participate in this clinical trial through the physical examination, clinical laboratory test and interview by the investigators exclusion criteria: * clinically significant presence or treatment history of cardiovascular, hepatic, renal, gastrointestinal, respiratory, neurological, hematological, endocrine, psychiatric * clinically significant surgical history * clinically significant family history * clinically significant atopic syndrome * history of hypersensitivity or clinically significant hypersensitivity to drug including carbamazepine and related compounds * history of alcoholism or drug abuse or show a positive response to an abuse drug in the urine drug screening test * consistently consume alcohol or cannot stop drinking during the clinical trial * smoker * significant infection or inflammatory finding at screening visit * history of gastrointestinal disorders or surgery which may have an effect on the safety and pharmacokinetic evaluation of the investigational products (except for simple appendectomy and herniotomy) * have used prescription drugs or herbal medication within 2 weeks of initial administration or who have used over the counter(otc), health functional food or vitamins within 1 week of initial administration (but, if the other conditions are suitable according to the judgment of the investigator, they can participate in the clinical trial), or subjects who have expected to take it * have participated in any clinical trial (or bioequivalence study) and administered any investigational product within 6 months * positive for hbsag, anti-hcv and hiv antigen-antibody reaction tests at screening * have donated any whole blood or apheresis or received blood transfusion within 3 months of initial administration of this clinical trial * have dietary restrictions or cannot take the food provided by the institution * cannot communicate reliably with the investigator * subjects who are determined by the investigator to be ineligible for participation in this clinical trial due to clinical laboratory test results or other reasons
epsilon aminocaproic acid (eaca) for the reduction of blood loss in total hip arthroplasty (tha)

Conditions: Degenerative Joint Disease; Osteoarthritis

Summary: you are being asked to take part in this research study because you are scheduled to have total hip replacement (arthroplasty) surgery. the goal of this study is to evaluate the effectiveness of the drug, epsilon aminocaproic acid (eaca), in decreasing the need for patients to receive blood after surgery. currently, eaca is approved by the federal drug administration (fda) to treat a patient who is bleeding. the investigators plan to use eaca to prevent bleeding during and after surgery; use of this drug as a means of preventing bleeding is not currently approved by the fda.

the goal of this prospective randomized study is to evaluate the effectiveness of a drug, epsilon aminocaproic acid (eaca), in reducing the frequency of postoperative blood transfusion following primary total hip arthroplasty. in our institution, up to 40% of patients with a preoperative of 13.5 g/dl or less undergoing total hip arthroplasty will require a blood transfusion. fibrinolytic drugs such as eaca and tranexamic acid (ta) have been shown to decrease blood loss during surgery and decrease the likelihood of blood transfusion during postoperative hospitalization.. both drugs decrease the body's ability to break down a blood clot, thus pushing the balance of blood clot formation and breakdown towards clot formation. this mechanism can decrease the amount of blood loss during and after a surgical procedure. the haemostatic effect of eaca has been investigated in multiple studies with the majority showing a positive effect on postoperative hemoglobin levels and decreased blood transfusion rates. though several studies exist revealing the effective and safe use of perioperative ta, a similar drug to eaca, there is a paucity of information on the use of eaca in total joint arthroplasty.

Eligibility criteria:
inclusion criteria: 1. scheduled for a primary total hip arthroplasty to be performed at the mayo clinic 2. a preoperative hemoglobin between 10.0 and 13.5 exclusion criteria: 1. a preoperative hemoglobin less than 10.0 or greater than 13.5 2. revision arthroplasty; 3. arthroplasty performed for acute fracture 4. inability to obtain informed consent; 5. allergy to eaca 6. pregnancy 7. history of coronary stenting \< 6 months 8. heart valve replacement; 9. renal disease, 10. coagulopathy, dic, 11. embolic stroke

Keywords: epsilon aminocaproic acid blood loss total hip arthroplasty reduction in blood transfusions amicar
efficacy of ultrasound guided hyaluronic injection in treatment of trigger finger

Conditions: Trigger Digit

Summary: comparing the efficacy of ultrasound guided hyaluronic injection with ultrasound guided corticosteroid injection in treatment of trigger finger

randomized controlled trial which designed to compare the success rate, recurrence rate and functional outcomes of patients with trigger finger whom was treated with ultrasound guided hyaluronic acid injection to ultrasound guided corticosteroid injection

Eligibility criteria:
inclusion criteria: * age \> 20 years old * quinnell grade i, ii, iii * acute (\< 6 months) exclusion criteria: * quinnell grade iv * diabetes mellitus * rheumatoid arthritis * pregnancy * patient with prior injection or surgery of trigger finger * patient who are allergy to hyaluronic acid

Keywords: trigger finger trigger thumb ultrasound guided hyaluronic acid
an observational study of mabthera/rituxan (rituximab) in patients with sero-positive rheumatoid arthritis who are non-responders or intolerant to a single tnf-inhibitor (portsmab)

Conditions: Rheumatoid Arthritis

Summary: this observational study will assess the long-term efficacy and safety of mabthera/rituxan in routine clinical practice in patients with sero-positive rheumatoid arthritis who are non-responders or intolerant to a single tumour necrosis factor (tnf) inhibitor. data will be collected from each patient over 2 years.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * rheumatoid arthritis positive for rheumatoid factor and/or anti-ccp * non-responder or intolerant to single tnf-inhibitor therapy * initiating treatment with mabthera/rituxan exclusion criteria: * contra-indications to mabthera/rituxan therapy
specific modified exercise program for low back pain in racketlon players

Conditions: Sports Physical Therapy

Summary: to compare the effects of conventional exercise protocol and specific modified exercise program to prevent low back pain in racketlon players.

racketlon is a combination sport in which competitors play a sequence of the four most popular racket sports: table tennis, badminton, squash and tennis. squash (racquet sport) is an intermittent high-intensity competitive racquet sport that requires quick movements as maintaining control over the placement of the ball with the greatest spatial awareness that is played globally through racquet sports are enjoyed throughout the world and are increasing in their popularity. since this game encumbers a high level of fitness from the players, who are usually active for the majority of the playing time. squash players are physically challenged as they are engaged in continuous repetitive training and frequent participation in game to improve their fitness and skills. the purpose of this study is to find the effects of modified exercise program on lbp in racketlon players. the modified exercise program is a 5-week linear periodization program, which had effects on maximal strength and speed on elite squash players. this study will find whether this 5-week linear periodization program has an effect to prevent low back pain in racketlon players.

Eligibility criteria:
inclusion criteria: * active male racketlon player involved in sport activities for at least 3 times per week * age between 20-30 years. * players having ≥ 2 episodes of mechanical low back pain in past 6 months. exclusion criteria: any upper and lower limb injury. * history of metabolic diseases. * history of recent fractures. * history of spinal radiculopathy
goal-directed intraoperative fluid management using flotrac© monitoring in high-risk neurosurgical patients

Conditions: Intracranial Aneurysm; Brain Edema; Scoliosis; Surgery

Summary: this is a prospective, randomized controlled trial to determine if using flotrac/ev1000 system in neurosurgical patients undergoing craniotomies for aneurysm repair or tumor resection complicated by cerebral edema, or complex spinal surgery including multi-level scoliosis correction, is a more effective way of monitoring fluid.

we hypothesize that the ability to assess volume status and fluid responsiveness with information gained from edwards flotrac/ev1000 system coupled with a goal-directed therapy fluid management algorithm can make a difference in patient outcomes. our specific aims are: * demonstrate goal-directed therapy (gdt) in fluid management improves peri-operative fluid balance * demonstrate gdt improves pulmonary function and organ oxygenation * demonstrate gdt reduces necessary therapeutic interventions in the peri- operative period * demonstrate gdt reduces hypotensive episodes in the peri-operative period outcomes we will study the consequences of goal-directed fluid therapy that employs use of dynamic indicators seen on flotrac/ev1000 system by measuring the following: * pulmonary status * time to extubation * alveolar-arterial (a-a) gradient of oxygen * requirements for supplemental oxygen * organ oxygenation * serum lactate * arterial blood gas values (ph, hco3, co2, o2) * length of stay (los) * in hospital, defined as time from operation start to eligibility for discharge from hospital according to surgeon in accordance with pre-define criteria * in icu/pacu, defined as time from operation end to eligibility for discharge from intensive care according to attending intensivist in accordance with pre- define criteria * fluid balance * inputs and outputs (i/os) of all measurable fluids (i.e. blood, crystalloid, colloid) in peri-operative period, through and including duration of intensive care or the next 24-48 hours after completion of surgery * drugs administered for fluid management (i.e. mannitol, vasopressors) * pre-operative and post-operative body weights and twice-daily weights via bed weights * hypotension * number, duration and severity (i.e. minimum blood pressure) of hypotensive episode, defined as map \<65

Eligibility criteria:
inclusion criteria: * neurosurgical patients with concerns for decreased intracranial compliance; * orthopedic spine patients; * patients scheduled to undergo neurosurgical interventions that include any of the following will be eligible: intracranial aneurysm repair; or, major spine surgery. exclusion criteria: * patients with permanent cardiac arrhythmias; * patients with severe aortic regurgitation; * patients with intra-aortic balloon pump (iabp); * patients undergoing emergency surgery; and, * women who are pregnant and/or nursing will be excluded.
non-invasive assessment of the current state of hydration in children by ultrasound

Conditions: Gastroenteritis; Diabetes Mellitus (Ketoacidosis)

Summary: children with clinical signs of severe dehydration will be examined by ultrasound in a supine position during admission. children aged between 1 and 15years will be divided into three weight groups: 10-20kg, 20-30kg, 30-50kg. early after admission 1st measurement of diameters of vena cava inferior (vcimax, vcimin) during breathing cycles and diameters of both venae jugulares (vji dx max, min, vji sin max, min) before and after passive leg raise maneuver will be recorded. after a defined fluid infusion within 60 minutes, a second examination will be evaluated and compared with the first one. the investigators considered also echocardiography to measure co changes however they wanted to make it as simple as it might be at emergency during the night shift without an experienced cardiologist.

only children admitted to the hospital with clinically detectable dehydration (weight loss, dry skin, sunken eyes, no tears) will be evaluated. weight, noninvasive blood pressure measurement, pulse rate will be recorded. measurements would be performed with an ultrasound probe with a low frequency (2-5 mhz), a curved array transducer will be used. in the supine position, the ultrasound probe will be placed in the substernal area, in the longitudinal and transversal plane, 1 cm caudal to the confluence of the hepatic veins, and it will be operated in m-mode. the largest (vcimax) and smallest (vcimin) diameters will be measured and the collapsibility index will be calculated (according to the formula: vcimax - vci min / vci max x100). immediately after this examination measurement of the right vjimax, min and the left vjimax, min will be measured again in the supine position, then after passive leg raise (lifting the lower limbs 45st. for at least 1minute ) vjimax, min. and left vjimax, min will be measured. the collapsibility index for right and left vji would be calculated according to the formula: vjimax - vji min / vji max x100. after a defined fluid infusion (20ml/kg, but the maximum volume will be limited to 500ml, this means that over 25kg weight we would apply not more than 500ml) within 60 minutes. a control examination of vci, right vji, and left vji will be evaluated the same way as first and compared with the previous one.

Eligibility criteria:
inclusion criteria: * previously healthy children * history and clinical signs of dehydration (gastroenteritis, diabetic ketoacidosis) exclusion criteria: * congenital heart diseases * intestinal obstruction * any signs of abdominal hypertension * any illnesses known to affect the volume status

Keywords: children dehydration ultrasound vena cava inferior vena jugularis passive leg raise
study to demonstrate equivalence of formoterol 12 and 24 µg delivered via two types of single dose dry powder inhalers (concept1 and aerolizer)

Conditions: Asthma

Summary: this study is designed to demonstrate that formoterol 12µg and 24µg delivered by a new inhalation device (concept1) are equivalent to the corresponding dose of formoterol delivered by the aerolizer device in terms of efficacy, in patients with persistent asthma.


Eligibility criteria:
inclusion criteria: * history of asthma attacks * forced expiratory volume in 1 second (measure of how well the lungs are working) is greater than 60% of the predicted value exclusion criteria: * asthma is not stable: patients were admitted to hospital or received emergency room treatment * patients whose asthma drugs need changing within the month prior to the start of the study

Keywords: asthma adults b2 agonist formoterol
a comparison of the safety and effectiveness of fluconazole or clotrimazole in the treatment of fungal infections of the mouth and throat in patients with aids

Conditions: Candidiasis, Oral; HIV Infections

Summary: to compare the efficacy, safety, and tolerance of fluconazole single daily capsule for 14 days versus clotrimazole troche 5 x daily for 14 days in the treatment of oropharyngeal candidiasis in patients with aids.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * cimetidine. exclusion criteria co-existing condition: patients with the following are excluded: * known history of intolerance or allergy to imidazoles or triazoles, or the non-azole components of clotrimazole troches (dextrose, cellulose, povidone, magnesium stearate). * moderate or severe liver disease defined by specified lab values. concurrent medication: excluded pending results of phase i studies to determine whether interaction between fluconazole and these agents occurs: * barbiturates. * phenytoin. * coumarin-type anticoagulants. * rifampin. * oral hypoglycemics. * cyclosporin. patients with the following are excluded: * known history of intolerance or allergy to imidazoles or triazoles, or the non-azole components of clotrimazole troches (dextrose, cellulose, povidone, magnesium stearate). * unable to tolerate oral medication. * moderate or severe liver disease defined by specified lab values. * life expectancy \< 4 weeks. * unable or unwilling to be followed at the same center for the conduct of this study. prior medication: excluded within 3 days of study entry: * other antifungal agents. * excluded pending results of phase i studies to determine whether interaction between fluconazole and these agents occurs: * barbiturates. * phenytoin. * coumarin-type anticoagulants. * rifampin. * oral hypoglycemics. * cyclosporin. patients meeting cdc criteria for diagnosis of aids, or having serologic or virologic evidence of hiv infection (but without aids-defining opportunistic infections as of yet). * patients who have given informed consent in writing to their participation in the study. * patients with signs of oropharyngeal candidiasis, i.e., with typical white plaques.

Keywords: aids-related opportunistic infections fluconazole clotrimazole acquired immunodeficiency syndrome candidiasis, oral
pituitary gland enlargement was first diagnosed by optical coherence tomography (oct)

Conditions: Pituitary Mass; Diagnoses Disease

Summary: oct is now an established way to measure the thickness of the retinal nerve fiber layer (rnfl) in the retina of the eye. the thickness of the rnfl is always a reflection of the number of the rnfs in any particular area of the retina. each single rnf runs a long course starting from the cell body which is the retinal ganglion cell in the retina and ends in the thalamus of the brain where it relays visual information to other nerve cell in the thalamus. along this long course rnfs are in close anatomical relationship with the pituitary gland crossing just above this gland about midway along their course. hence enlargement of this gland can interfere with the rnfs.

the inferior chiasmal syndrome is known to be caused by pituitary gland enlightenment because the pituitary gland lies just below the optic chiasma. the visual rnfs are organized in a very specific way along their long course from the retina to the lateral geniculate body (lgb) in the thalamus. pituitary enlargement would compromise particular rnfs. it is well known and established that pituitary enlargement, if not properly treated in time, would possibly cause bitemporal hemianopia due to interference with the crossing rnfs of the nasal half of each retina. in this study pituitary enlargement was suspected by oct findings while the patient still had perfect peripheral visual field in each eye.

Eligibility criteria:
inclusion criteria: * healthy patients with frequent or persistent headache of unknown reasons. exclusion criteria: * patients who were previously diagnosed with or treated from pituitary enlargement